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The utility of screening for deep venous
thrombosis in asymptomatic, non-ambulatory
neurosurgical patients
Meghan Dermody, MD, MS,a Jean Alessi-Chinetti, RVT, RDMS,b Mark D. Iafrati, MD, RVT,c and
James M. Estes, MD,c Boston, Mass
Objectives: Decisions regarding deep venous thrombosis (DVT) prophylaxis are complicated in neurosurgical patients
because of the potential for catastrophic bleeding complications. Screening with venous duplex ultrasound (VDUS) may
improve outcomes, but can strain hospital resources. Since there is little data to guide VDUS surveillance, we investigated
the utility of a comprehensive VDUS screening program in neurosurgical patients.
Methods:Medical records of patients admitted to the neurosurgical service at a university-affiliated hospital from October
2007 through January 2010 who underwent weekly VDUS of the lower extremities until ambulatory or discharged were
retrospectively reviewed. Demographics, comorbidities, interventions, and use of DVT prophylaxis were recorded. All
patients in this study were asymptomatic for clinical evidence of DVT. When DVT was identified, VDUS reported its
location and progression.
Results: One hundred seventy-four consecutive patients were screened according to the established protocol. They had
312 VDUS studies, 68 (21.8%) of which were positive in 40 (23%) unique patients; 10 were bilateral and two
catheter-related. There were no documented pulmonary emboli in this series. Seventeen patients (37.7%) had isolated calf
DVT, four of which were bilateral (totaling 21 thrombi), and 9 (20%) had coexistent thrombi in calf and proximal veins.
Of the 21 isolated calf DVTs, 15 had follow-up studies and two progressed to the popliteal or ileofemoral vein on
follow-up (13.3%). Mechanical prophylaxis was uniformly utilized, but chemical prophylaxis varied based on surgeons’
assessment of bleeding risk. DVT developed in 19.3% (28/145) of patients receiving prophylactic medication (unfrac-
tionated heparin or low-molecular weight heparin) and 41.4% (12/29) receiving no chemoprophylaxis (P < .001). The
only patient characteristic that correlated with DVT risk was a body mass index <30 (9.1% vs 29.4%, P  .01).
Conclusions: Despite the uniform application of mechanical DVT prophylaxis and the use of chemoprophylaxis in a
majority of patients, we found a 23% incidence of DVT in these hospitalized, nonambulatory, neurosurgical patients. No
patients with isolated calf DVT had an embolic complication but 13.3% progressed proximally in short-term follow-up.
While chemical prophylaxis significantly reduced DVT risk, no factor was sufficiently predictive to exclude patients from
screening. These data substantiate the importance of full leg VDUS screening and maximizing DVT prophylaxis in this
high risk population. (J Vasc Surg 2011;53:1309-15.)
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uThe incidence of deep venous thrombosis (DVT) in
high-risk neurosurgical and trauma patients is reported to
be 6% to 43%.1-3 These patients are prone to venous
thromboembolism (VTE) due to long operative times,
release of thrombogenic substances in the brain, prolonged
bed rest or immobility, use of glucocorticoid therapy, and
osmotic treatment (mannitol) for brain edema.4 For this
reason, many studies have attempted to determine the
safety of prophylactic anticoagulation in a population at
high risk for intracranial hemorrhage (ICH). The literature
supports the use of chemical prophylaxis in neurosurgical
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doi:10.1016/j.jvs.2010.10.115atients as it significantly decreases DVT rates withminimal
leeding risk.4,5 Despite these general recommendations,
hemical prophylaxis is still commonly withheld by clini-
ians who believe anticoagulation poses a “prohibitive risk”
o their individual patients who might be at particularly
igh risk for bleeding.
Venous duplex ultrasound (VDUS) is an accurate, non-
nvasive method of diagnosing DVT.6 The goal of screen-
ng is to limit VTE by initiating treatment, either therapeu-
ic anticoagulation or inferior vena cava filter (IVCF), as
arly as possible.7 Due to their high DVT rates, neurosur-
ical patients may therefore warrant screening.1,3 In their
ystematic review of the current literature, Raslan et al5
eported the lack of standardized DVT surveillance proto-
ols in the United States due to the lack of randomized
ontrolled trials comparing a screening protocol with no
urveillance. They stated that, based on current data, sur-
eillance for DVT should be undertaken.
Hospital vascular laboratories have faced growing re-
uests for ultrasound studies and are often limited by
taffing and budget. We therefore sought to explore the
tility of our DVT screening program for neurosurgical
atients. While there seems to be consensus that screening
1309
p
w
s
(
(
t
l
o
t
p
(
2
y
w
p
w
l
B
(

l
s
o
c
t
o
l
F
p
T
t
L
S
P
P
F
O
t
T
JOURNAL OF VASCULAR SURGERY
May 20111310 Dermody et alis appropriate in this population, we wanted to clarify the
benefit or lack thereof for scanning calf veins, repeating
studies, and whether there are risk factors or case types that
should impact patient selection or the intensity of screen-
ing.
METHODS
Approval by the Institutional Review Board at Tufts
Medical Center was obtained prior to presenting and pub-
lishing this data. A list of consecutive neurosurgical patients
who underwent screening with weekly VDUS of the bilat-
eral lower extremities between October 2007 and January
2010 was obtained from the vascular laboratory at our
university-affiliated hospital. All VDUS studies were per-
formed in an accredited vascular laboratory and interpreted
by staff vascular surgeons according to the Intersocietal
Commission for the Accreditation of Vascular Laboratories
guidelines. The screening protocol in place at the time of
our study required all neurosurgical inpatients whowere, or
were expected to be, nonambulatory for 7 or more days be
screened on a weekly basis with bilateral lower extremity
VDUS. Only patients without clinical signs suggestive of
DVT were included in our study.
The following comorbidities, known to be associated
with a higher risk for DVT according to the American
Venous Forum, were recorded for each patient: congestive
heart failure, obesity (body mass index [BMI] 30), can-
cer, history of DVT, pregnancy, tobacco use, and history of
hypercoagulable disorder. Each patient’s pathology (ICH,
stroke, head trauma, aneurysm, tumor, or other), interven-
tion (endovascular coiling or clipping, craniotomy, stereo-
tactic biopsy, spine surgery, transsphenoidal surgery, or
other), and use of chemoprophylaxis (unfractionated hep-
arin [UFH] or low-molecular weight heparin [LMWH])
was recorded and tested for association with DVT using 2
analysis and Fisher’s exact test. A P value of .05 was con-
sidered significant for this study.
The main outcome measures were development of any
lower extremity DVT and development of isolated calf
DVT (gastrocnemius, soleal, posterior tibial [PT], per-
oneal). The secondary outcome measures were progression
of distal thrombus to proximal vessels, development of
pulmonary embolism, association of comorbidities with
development of DVT, association of prophylactic anticoag-
ulation with development of DVT, and bleeding complica-
tions. We tested the null hypothesis by evaluating the
incidence of isolated calf DVT in this population and clot
progression over time.
RESULTS
BetweenOctober 2007 and January 2010, 174 consec-
utive patients admitted to the neurosurgical service with
nonambulatory status were screened with weekly VDUS
until ambulatory or discharged. A total of 312 VDUS
studies were performed in these 174 patients. A frequency
graph depicting the number of scans each patient had can
be seen in the Fig. Of these 312 studies, 68 (21.8%) were
positive in 40 (23%) unique patients. Ten studies were tositive for DVT in bilateral lower extremities and two
ere catheter-related. Ten of the 40 patients had positive
cans after initial negative studies. Seventeen patients
42.5%) had isolated calf DVT, four of which were bilateral
21 thrombi in total), and nine (20%) had coexistent
hrombi in calf and proximal veins. Table I has listed the
ocation and incidence of the initial DVT recorded for each
f our 40 DVT patients. Note that among these 40 pa-
ients, there were a combined total of 80 thrombi as 16
atients had either bilateral or multiple levels of DVT.
The mean age of our study population was 62.1 years
range 11-100), 47% were male, and the average BMI was
8.4  7.5. Of those with DVT, the mean age was 61.8
ears (range 11-92), 42.5% were male, and average BMI
as 26.1  5.7. None of the recorded comorbidities,
athologies, or interventions was significantly associated
ith DVT except for BMI, craniotomy, and chemoprophy-
axis (Table II). DVT occurred in five of 55 patients with
MI 30 (9.1%) vs 35 of 119 patients with BMI 30
29.4%, P .01). This increased risk for patients with BMI
30 is independent of the presence of malignancy or of the
ength of hospital stay. Thirty-seven percent of patient
tatus post craniotomy vs 19% of patients without craniot-
my developed DVT. This association was not affected by
hemoprophylaxis use as an equivalent percentage of pa-
ients without chemoprophylaxis (41%) compared with the
verall cohort (50%) developed DVT. Chemical prophy-
axis was provided for 145 (83.3%) patients. Themajority of
ig. Frequency of venous duplex ultrasound (VDUS) scans per
atient.
able I. Location and incidence of initial deep venous
hrombosis (DVT)
ocation of thrombus Incidence, % (No.)
oleal or gastrocnemius vein 34 (27/80)
osterior tibial or peroneal vein 17 (14/80)
opliteal vein 15 (12/80)
emoral vein 34 (27/80)
f the 40 patients with DVT, 16 had either bilateral or multiple levels of
hrombus.
he total number of initial DVT was therefore 80.hese patients were given 5000 units of unfractionated
o
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Volume 53, Number 5 Dermody et al 1311heparin either two or three times daily. Two patients were
given once daily enoxaparin. DVT developed in 19.3%
(28/145) of patients receiving chemoprophylaxis and
41.4% (12/29) receiving no chemical prophylaxis (P 
.01).
Of the isolated calf DVTs, three patients did not receive
Table II. Association of comorbidities, interventions, and
Predictive factors (n) Positive VDUS (%) Nega
Sex
Male 17 (42.5)
Female 23 (57.5)
Race
White 32 (82.1) 1
Black 2 (5.1)
Hispanic 3 (7.7)
Asian 2 (5.1)
CHF
Yes 2 (5)
No 38 (95) 1
Obese
Yes 5 (12.5)
No 35 (87.5)
Cancer
Yes 8 (20)
No 32 (80) 1
History of 0 (0)
History of DVT
Yes 1 (2.5)
No 39 (97.5) 1
Tobacco use
Yes 9 (22.5)
No 16 (40)
Former 2 (12.5)
Unknown 10 (25)
Endovascular
No 29 (72.5) 1
Yes 11 (27.5)
Craniotomy
No 25 (62.5)
Yes 15 (37.5) 1
Stereotactic biopsy
No 39 (97.5) 1
Yes 1 (2.5)
Spine surgery
No 31 (77.5)
Yes 9 (22.5)
Stroke
No 39 (97.5) 1
Yes 1 (2.5)
Trauma
No 34 (85) 1
Yes 6 (15)
Intracranial hemorrhage
No 21 (52.5)
Yes 19 (47.5)
Aneurysm
No 25 (62.5) 1
Yes 15 (37.5)
Tumor
No 32 (80) 1
Yes 8 (20)
CHF, Congestive heart failure; DVT, deep venous thrombosis.
Obesity considered body mass index 30.any treatment, five were maintained on prophylactic doses ff anticoagulation with twice daily UFH, five were treated
ith therapeutic anticoagulation (LMWH in one, warfarin
n three, intravenous heparin in one), and four were treated
ith IVCF. The characteristics of our isolated calf DVT
ohort can be seen in Table III.
Twelve of the 17 patients with isolated calf DVT had
ology on incidence of deep venous thrombosis
DUS (%) Total (%) 2 Fisher’s exact
8.5) 82 (47.1) 0.5144
1.5) 92 (52.9)
6.1) 134 0.5714
.5) 12
.2) 10
1.2) 17
) 6 0.5228
7) 168
7.3) 55 0.0119
2.7) 119
2.7) 25 0.2077
1.3) 141
) 8
.7) 7 1.0
5.3) 167
1.5) 38 0.6023
0.5) 57
1) 33
7) 46
6.9) 132 0.5945
3.1) 42
9.4) 133 0.0466
0.6) 41
9.3) 172 0.4079
.7) 2
1.6) 127 0.7006
8.4) 47
6.3) 168 1.0
.7) 6
0.6) 142 0.7787
9.4) 32
0) 88 0.6604
0) 86
5.4) 126 0.1873
4.6) 48
8.1) 150 0.2507
1.9) 24path
tive V
65 (4
69 (5
02 (7
10 (7
7 (5
15 (1
4 (3
30 (9
50 (3
84 (6
17 (1
09 (8
8 (6
6 (4
28 (9
29 (2
41 (3
28 (2
36 (2
03 (7
31 (2
26 (1
08 (8
33 (9
1 (0
96 (7
38 (2
29 (9
5 (3
08 (8
26 (1
67 (5
67 (5
01 (7
33 (2
18 (8
16 (1ollow-up studies performed. Three of these patients had
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May 20111312 Dermody et albilateral calf DVTs, therefore totaling 15 calf DVTs with
follow-up in this study group. Of these 15 limbs with
isolated calf DVT, 8 persisted without propagation during
mean follow-up of 17 days, 4 resolved (1 patient was
treated with therapeutic LMWH, 1 with warfarin, 1 with
prophylactic UFH, and 1 was untreated) over a mean
follow-up of 26 days, and 2 (13.3%) progressed proximally
(one gastrocnemius thrombus to the popliteal vein (POP),
one soleal thrombus to the ileofemoral vein) by 8 and 11
days of follow-up, respectively. Of the two patients with
propagation, one (POP) was treated with warfarin and one
(ileofemoral) underwent thrombectomy and IVCF place-
ment in addition to receiving warfarin therapy. In compar-
ing calf muscle vein propagation rates with tibial vein
propagation rates, there was no statistical significance be-
tween the two groups (P  .3). Of the 5 patients without
follow-up studies, 2 had IVCF placed, 1 was treated with
prophylactic UFH, 1 received warfarin therapy, and 1 was
not treated at all. No patients developed PE in this study.
Bleeding complications occurred in three of the 174
patients. The first patient had undergone craniotomy for
excision of meningioma and subsequently developed ex-
tensive ileofemoral DVT 2 weeks postcraniotomy requiring
thrombectomy, IVCF placement, and warfarin therapy.
She re-presented 7 weeks later with mental status changes
and was noted to have hydrocephalus requiring ventriculo-
peritoneal (VP) shunt placement. Three months later she
developed VP shunt infection, was placed on intravenous
Table III. Characteristics of patients with isolated calf De
Patients
Age
(years)
Race,
gender
DVT
prophylaxis
Prior negative
study (No.) Location of t
1 32 WM SQH TID 0 Calf
2 65 WF SQH BID 0 Calf
3 62 WF None 3 Calf
4 51 WM SQH BID 0 Calf
5 87 WM SQH BID 1 Bilateral calf
6 50 WM None 0 Calf
7 44 HM None 0 Calf
8 79 ? M SQH TID 0 Calf
9 59 WF SQH TID 0 Calf
10 74 WM SQH BID 0 Calf
11 67 WF SQH TID 0 Bilateral calf
12 74 WF SQH BID 0 Bilateral calf
13 64 WM SQH BID 0 Bilateral calf
None 0 Bilateral calf
unilateral
14 89 WF SQH BID 0 Calf
15 72 BF SQH BID 0 Calf
SQH BID 0 Ileofemoral
16 85 HF SQH BID 1 Calf
17 35 WM SQH TID 1 Calf
B, Black; F, female; H, Hispanic; IVCF, inferior vena cava filter; LMWH, lo
heparin given three times daily; SQH BID, subcutaneous unfractionated heheparin, and thereafter developed a small intraventricular nemorrhage. The two other patients did not have DVT but
ere both therapeutically anticoagulated on intravenous
eparin (one for ST-elevation myocardial infarction, one
or stroke) and both developed ICH, the former requiring
raniotomy due to bilateral uncal and right tonsillar herni-
tion. No patients on prophylactic doses of anticoagulation
ad bleeding complications.
Seven patients in this cohort died, two of which were
ositive for DVT. The first patient presented with hyper-
ensive ICH and was subsequently diagnosed with il-
ofemoral DVT treated with IVCF. He went on to develop
eningitis and ventriculitis, and thereafter was noted to
ave a fixed, dilated pupil and agonal breathing. His family
eclined intubation and he subsequently expired. His re-
piratory failure was thought to be due to a central process
nd not PE, although no imaging studies or post mortem
xamination was done to prove this. The second patient
resented with spontaneous subarachnoid hemorrhage
ith subsequent multiorgan system failure. She developed
calf and POP DVT treated with IVCF. Three weeks into
er hospital course, she remained unresponsive and ex-
ired.
ISCUSSION
Despite application of mechanical and chemical DVT
rophylaxis, we found a 23% incidence of DVT in hospital-
zed, nonambulatory, neurosurgical patients. This inci-
ence is comparable to other studies.1,3 In testing for our
nous thrombosis
bus
Follow-up studies
(No.; over x days) Progression Treatment
4 (25) Persistent SQH BID
1 (7) Persistent IVCF
1 (3) Persistent Warfarin
1 (11) Persistent None
2 (75) Unilateral persistence,
Unilateral
resolution
LMWH
0 Unknown IVCF
1 (3) Persistent SQH BID
1 (4) Persistent IVCF
1 (7) Resolved IV heparin
0 Unknown None
1 (9) Unilateral persistence,
Unilateral
resolution
Warfarin
0 Unknown SQH BID
1 (8) Yes None
eal
1 (13) Persistence Warfarin
5 (34) Resolved in 13 days SQH BID
1 (11) Yes SQH BID
1 (6.5 months) Resolved Thrombectomy,
warfarin, IVCF
0 Unknown IVCF
0 Unknown Warfarin
lecular weight heparin; M, male; SQH TID, subcutaneous unfractionated
iven twice daily; W, White; ?, unknown.ep ve
hrom

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Volume 53, Number 5 Dermody et al 1313DVT to have thrombi isolated to the calf veins, giving us an
overall incidence of isolated calf DVT of 9.8%. While this
number is significant, only 13.3% progressed proximally
and none developed an embolic complication.
The location of a thrombus is of uncertain significance
in hospitalized patients with asymptomatic DVT. Asymp-
tomatic thrombi are generally smaller, less frequently oc-
clusive, and usually located in the tibial or calf muscle veins
compared with symptomatic thrombi.8 As many previous
studies have shown, rates of proximal extension of calf DVT
range from 4% to 34%.9,10 One of our questions was
whether asymptomatic isolated calf DVT is likely to prop-
agate or cause PE. Masuda et al10 prospectively studied
asymptomatic patients with isolated calf DVT to look for
rates of VTE, resolution, and post-thrombotic syndrome.
By following 58 limbs over 6 months, they found a 4%
propagation rate and no PE events. Eighty-eight percent of
limbs had complete lysis by 3 months leading them to
conclude that isolated calf DVT have “low risk for PE,
proximal extension, and development of post-thrombotic
syndrome”. They noted that if propagation occurs, it is
usually within the first 2 weeks of initial diagnosis.
It has been reported that almost half of symptomatic
patients undergoing VDUS have calf thrombus (gastrocne-
mius, soleus, PT, peroneal)9 which then must propagate to
thigh veins (POP, femoral [FV], common femoral (CFV])
prior to being a risk for PE. A recent retrospective study
performed by Lautz et al11 looked at all venous examina-
tions (outpatient, inpatient, symptomatic, asymptomatic)
performed in their vascular laboratory for the rate of iso-
lated gastrocnemius and soleal vein thrombosis (IGSVT).
They found an incidence of 10.4% of IGSVT in patients
with lower extremity DVT and an overall incidence of 2% of
IGSVT among all VDUS studies over a 5-year time period.
Their VTE rate was 18.7%, which included progression to
the PT and peroneal veins. Their rate of PE for patients
with IGSVT was 5.9% without anticoagulation, 4.2% with
prophylactic anticoagulation, and 3.7% with therapeutic
anticoagulation. In comparison, a study performed byMac-
donald et al12 looking at the natural history of IGSVT
followed 135 limbs with IGSVT over 3 months with serial
VDUS and showed a DVT rate of 16.5% (13.3% to PT or
peroneal, 3% to POP, and none to FV, CFV, or iliacs).
There were no PE events in this cohort. Comparing these
studies with ours, we found 34% of initial clots to be
IGSVT. In comparing the rates of propagation for IGSVT
vs isolated tibial DVT, we found two of the 27 IGSVT
propagated versus none of the tibial DVTs (P  .3). This
high incidence of IGSVT and rate of propagation supports
screening the calf muscles.
Meissner et al8 followed isolated calf DVTs to evaluate
their rate of propagation to proximal veins and found a 16%
rate occurring over a median of 29 days (range 4-34 days).
Among those with isolated calf DVT, one patient (3%) had
PE documented by ventilation-perfusion scan 33 days after
presentation and was noted to be on anticoagulation at the
time without evidence of proximal propagation on VDUS.
In summary, the high percentage of DVTs isolated to calf geins (42.5%) in our series of nonambulatory, neurosurgical
atients, and the short-term proximal propagation rate of at
east 13% is consistent with the literature and affirms the
linical significance of this disease process.
Based on our initial impression from interpreting
DUS studies in our laboratory, we began this study with
he impression that scanning calf veins may not be clinically
elevant and that screening in general may not be effective.
he vascular technologists reported challenges in assessing
he calves in this difficult population, due to bed rest,
mmobility, and sedation. Their impression was that these
cans took a long time to perform and their value was not
lear. In our setting, the majority of time spent per study
nvolves scheduling, travelings for portables, positioning
he patient, communicating with staff, and documenting.
e found that, on average, actual scanning time for a
omplete screening study was 11 minutes, with the calf
omponent consuming only 2.2 minutes. In addition, we
ere surprised to find a high incidence of isolated calf DVT
42.5%), as well as a variety of interventions pursued in
hese cases. Thus, the discovery of an isolated calf DVT
ook an additional 2.2 minutes per scan and changed
herapy in more than half of these patients. In this retro-
pective series, the diagnosis of isolated calf DVT resulted
n 23.5% of patients increasing to therapeutic anticoagula-
ion and another 23.5% receiving IVCF. Finally, in recog-
ition of the fact that calf DVTs pose significant risk only
ith propagation to POP or ileofemoral veins, we consid-
red options to limit VDUS to the first and/or last screen-
ng study for each patient, positing that this approach
ould identify all proximal DVTs as soon as possible and
ould alert the clinician to the presence of a calf DVT prior
o discharge. However, we found that such an approach
ould not be effective in our setting since 25% of patients
ound to have calf DVT on screening had a normal study on
heir initial screen. In addition, the majority of patients
55.7%) only had a single screening VDUS and therefore a
lan to study the calf veins only on the “last study” before
ischarge or ambulation would have resulted in the need
or additional studies prior to discharge. Based on these
ata, we plan to continue our protocol of comprehensive
eekly VDUS screening (including calf veins) in nonam-
ulatory, neurosurgery patients; to encourage chemical and
echanical DVT prophylaxis whenever possible; and to
ncourage our neurosurgical team to reassess the risk vs
enefit analysis of anticoagulation when DVT is diagnosed
s a result of screening VDUS.
A statistically significant inverse correlation between
besity (BMI30) and DVT occurrence was noted in our
nalysis. Amultivariate analysis was not performed to justify
his association because our small sample sizes do not
arrant it. Instead, we looked at each parameter individu-
lly for confounders and were unable to find any. We
ostulated that, in this population, patients with multiple
omorbidities (ie, high cancer burden, elderly) may be
hinner than the general population, with BMI being a
urrogate for the degree of underlying illness and hypercoa-
uability rather than a relevant factor itself. Unfortunately,
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May 20111314 Dermody et althe small numbers in this series and the retrospective nature
of the report preclude further parsing the data. This unex-
pected finding warrants further investigation.
A positive association between craniotomy and DVT
development was also reported, as 37% of patient status
post craniotomy vs 19% of patients without craniotomy
developed DVT. To determine if this association was af-
fected by chemoprophylaxis use, we looked at the number
of craniotomy patients givenUFH either two or three times
daily (81%) vs no chemoprophylaxis (19%) and compared
their DVT rates. Twenty-nine percent of the group receiv-
ing chemoprophylaxis developed DVT vs 50% of the no
chemoprophylaxis group. Since this correlates with rates of
DVT development among the overall cohort, we can report
a non-confounded association of craniotomy with DVT
development.
Our high DVT rate in patients without chemoprophy-
laxis necessitates an evaluation of anticoagulation use
among our neurosurgical patients. Twenty-nine patients
(16.7%) were not receiving chemical prophylaxis at the time
of VDUS screening. Of these, 41.4% (12/29) developed
DVT. While the use of prophylactic anticoagulation re-
mains a complicated and imprecise risk vs benefit analysis
for neurosurgeons, these data demonstrate that the deci-
sion to withhold chemoprophylaxis is accompanied by a
markedly increased risk of DVT. These data are in accord
withmost of the contemporary literature and support wide-
spread use of chemical and mechanical DVT prophylaxis, as
well as VDUS screening,1,3,5 in this high risk population.
Additionally, had we chosen to only screen patients not
receiving chemoprophylaxis (n  145), 28 patients would
not have had their DVT diagnosed and treated, leading to
a significant amount of patients with high risk for VTE.
The use of IVCF in four patients with isolated calf DVT
also begs discussion. This practice resulted from an exten-
sion of the general principle that patients with DVT who
cannot be anticoagulated because of prohibitive bleeding
risks should be considered for placement of IVCF. How-
ever, since isolated calf DVTs are known to have low risk of
embolization9,11 and since IVCF carry their own set of
risks13-15 (both perioperatively and in the long term), we
believe the use of IVCF is not generally indicated in this
situation. This is consistent with the American College of
Chest Physicians guidelines, which recommend IVCF for
proximal DVT, implying but not specifically stating the
negative with regard to IVCF for calf DVT.16
The utility of the data in this report is greatly enhanced
by the uniformity of the patients reported: all being inpa-
tient, nonambulatory, neurosurgical patients. However,
there are several limitations of our study. First, it is a
retrospective, single center report on a relatively small
number of patients. Therefore, our ability to detect statis-
tically significant differences among subgroups or risk fac-
tors is limited. Second, there was no standardized pathway
for prophylaxis or treatment of DVT in these patients. It is
therefore possible that the clinician’s decision to withhold
chemoprophylaxis in some patients was based on an accu-
rate appraisal of an increased bleeding risk and that blanketrovision of chemoprophylaxis could have resulted in dis-
roportionately higher bleeding complications. Nonethe-
ess, the findings warrant further investigation with pro-
pective data collection against a control group.
ONCLUSIONS
In the setting of uniform application of mechanical
rophylaxis and the liberal use of chemical DVT prophy-
axis, except in patients deemed to be at “prohibitive bleed-
ng risk”, we found a 23% incidence of DVT in hospitalized,
onambulatory, neurosurgical patients. The risk of DVT in
atients receiving mechanical prophylaxis alone was 41.4%,
hereas the DVT rate in those receiving both mechanical
nd chemical prophylaxis was reduced to 16.7%. Chemo-
rophylaxis did not appear to contribute to bleeding com-
lications in this series. Of the patients with isolated calf
VT, none had an embolic complication and 13.3% pro-
ressed proximally. While chemical prophylaxis reduced
VT risk, no one comorbidity, intervention, or pathology
as sufficient to predict patients who could be excluded
rom screening. These data substantiate the importance of
DUS screening, maximizing DVT prophylaxis, and con-
inuing to screen calf veins on initial and follow-up VDUS
tudies in this high risk population.
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